Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
- Conditions
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Nancy Lin, MD
- Target Recruit Count
- 19
- Registration Number
- NCT03417544
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 64
- Registration Number
- NCT03412643
- Locations
- 🇺🇸
Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸Greater Baltimore Medical Center, Baltimore, Maryland, United States
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 7
- Registration Number
- NCT03329378
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Mount Sinai Beth Israel, New York, New York, United States
🇺🇸Mount Sinai West, New York, New York, United States
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
- Conditions
- Interventions
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 44
- Registration Number
- NCT03304080
- Locations
- 🇺🇸
Perlmutter Cancer Center NYU Langone, New York, New York, United States
🇺🇸New York Presbyterian Weill Cornell Medical Center, New York, New York, United States
🇺🇸New York Presbyterian Columbia Irving Comprehensive Cancer Center, New York, New York, United States
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 480
- Registration Number
- NCT03264547
- Locations
- 🇯🇵
National Hospital Organization Osaka National Hospital, Ōsaka, Osaka, Japan
🇯🇵Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 190
- Registration Number
- NCT03199885
- Locations
- 🇺🇸
Good Samaritan Hospital - Cancer Centers of Colorado, Lafayette, Colorado, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT03135171
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Yale University, New Haven, New York, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT03125928
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT03101748
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03006172
- Locations
- 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.